Important Findings from an In-depth Analysis of a Medication Incident
DOI:
https://doi.org/10.4212/cjhp.v60i4.190Abstract
INTRODUCTION
In May 2007, the Alberta Cancer Board released the document Fluorouracil Incident Root Cause Analysis1 for shared learning. The incident under analysis involved administration of a high dose of fluorouracil (4000 mg/m2; total dose 5250 mg) over 4 h instead of the intended 4 days. The protocol also included administration of a single dose of 100 mg cisplatin. The patient, a 43-year-old woman with advanced nasopharyngeal carcinoma, died 22 days later of the sequelae of fluorouracil toxicity, cumulative with cisplatin toxicity. The Institute for Safe Medication Practices Canada (ISMP Canada) was invited to provide external expertise for the root cause analysis of this event. Providing such assistance is one of ISMP Canada’s defined roles in the Canadian Medication Incident Reporting and Prevention System. The recommendations in the report1 were directed specifically toward safer management of high-dose fluorouracil protocols and may be relevant to the management of other chemotherapy agents and other high-alert medications. One of the recommendations was to disseminate widely the findings of the root cause analysis as a way to enhance awareness of the hazards identified. This article presents selected findings and excerpts from the report that are highly relevant to pharmacists. Root cause analysis is a structured process for a comprehensive system-based review of critical incidents to determine what happened, why it happened, and what can be done to reduce the likelihood of recurrence.2 Root cause analysis of a medication incident identifies hazards, issues, contributing factors, and underlying causes. This information is used to develop safeguards to prevent similar adverse events or to mitigate harm to patients if an incident does occur again.
Downloads
Downloads
Issue
Section
License
Copyright © Canadian Society of Healthcare-Systems Pharmacy.
After publication of a manuscript in the CJHP, the authors of the manuscript must obtain written permission from the CSHP (publications@cshp.ca) before reproducing any text, figures, tables, or illustrations from the work in future works of their own. If a submitted manuscript is declined for publication in the CJHP, all said rights shall revert to the authors. Please note that any forms (e.g., preprinted orders and patient intake forms) used by a specific hospital or other health care facility and included as illustrative material with a manuscript are exempt from this copyright transfer. The CJHP will require a letter from the hospital or health care facility granting permission to publish the document(s).